April 2, 2026 – Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced that it has been conditionally awarded a Texas Compassionate Use Program License. It is a vertically integrated license, allowing Cresco Labs to cultivate, process and dispense medical cannabis.
“Texas patients deserve access to consistent, quality medicine, and we’re excited to deliver it. Our track record in medical markets reflects our ability to build robust programs that put patients and communities first,” said Charlie Bachtell, CEO of Cresco Labs. “Winning a license in Texas through a merit-based application points to Cresco Labs’s deep regulatory expertise and thoughtful approach to meaningful local engagement. Organic licensing enables capital-efficient market entry, and our cash generation and balance sheet give us the financial flexibility to invest and grow a scaled, long-term platform.”
This license advances Cresco Labs’s disciplined, state-by-state growth strategy and secures access to one of the largest patient populations in the United States. Texas is the nation’s second-most populous state, approaching 30 million people, and continues to see ongoing legislative efforts to improve patient access and broaden qualifying conditions.
About Cresco Labs Inc.
Cresco Labs’ mission is to normalize and professionalize the medical marijuana industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust medical marijuana industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.
